Myriad Genetics Data Breach Exposes Sensitive Patient Information

Myriad Genetics Inc., a leading biotechnology company that specializes in genetic testing and precision medicine, disclosed a data breach.

The data breach was disclosed to the U.S. Securities and Exchange Commission on Nov. 2, 2026.

As a molecular diagnostic testing company, Myriad Genetics works directly with patients, healthcare providers and medical institutions across the country. Through its regular business operations, the company collects and processes personal and health-related information from individuals who use its testing and precision medicine services.

At this time, the specific details of the breach remain limited in the available public disclosures. Information about how the breach occurred, including the method of attack and the timeline of unauthorized activity, has not been detailed.

The categories of personal data that were exposed and the total number of individuals affected remain publicly undisclosed.

Myriad Genetics' response to the breach

Consumers who have used Myriad Genetics' genetic testing services or provided personal or health information to the company should monitor their mail and email closely for any official communications from the company in the coming weeks and months.

Any notification letter or email from Myriad Genetics may include important details about the nature of the breach, the specific types of personal or health information that were involved and what resources, services or next steps are available to those who were impacted.